New funds bring total financing since June 2025 to €20 million ($23.3 million), and unlock additional tranche from European Investment Bank loan Novadip aims to reach the market in 2028 and become a leader in limb sparing treatment Mont Saint-Guibert, Belgium,...
Responsible for supporting and maintaining the Quality Management System while ensuring compliance with internal procedures and GCP requirements. Employee or consultant. Key Responsibilities: Manage and maintain quality documents within the eQMS platform Scilife,...
During February and March 2026, the first two patients enrolled in our pivotal phase 3 trial for the treatment of Congenital Pseudarthrosis of the Tibia (CPT) were successfully implanted with NVD003 in Belgium and the US. NVD003, an autologous bone graft created from...
Trial aims to enroll 12 children at eight sites in EU and US.Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU).Novadip aims to become a leader in limb sparing treatment by 2027. Mont Saint-Guibert,...
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease Four young patients were treated at Cliniques universitaires Saint-Luc under compassionate use...
